AB
Abivax S.A.
ABVX · NASDAQ
$105.04 -1.68% (-$1.80)
1M -9.57%
Market Cap 6.72B €
P/E Ratio -
Div. Yield -
ROE 234.31%
Bulios Fair Price
$79.29
24.5% downside
Current Price
$105.04
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ABVX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
0 /100
Expensive P/B 14.76x
P/E N/A
EV/EBITDA N/A
Growth
100 /100
Growing Book val. growth 298.52%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
FCF margin N/A
Quality
0 /100
Poor ROIC 47.94%
ROE 234.31%
Asset turnover 0.00x
Debt
69 /100
Low Debt/Equity 0.07x
Current ratio 8.75x
Int. coverage -10.60x
Stability
39 /100
Moderate Beta -0.25x
EPS volatility 43.22%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ABVX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Marc de Garidel
Employees
80
Headquarters
Paris